+ Evidence in focus

Arthroplasty registry analysis (2025)

Smith+Nephew

Comparison of survivorship of cementless constructs in primary THA[1]

National Joint Registry for England, Wales, Northern Ireland, the Isle of Man and the States of Guernsey: 22nd Annual Report Hips, 2025: 1–180.

Available at: NJR 22nd Annual Report Hips 2025

Overview

- The UK National Joint Registry (NJR) reported on primary THA between 1 April 2003 and 31 December 2024, with a follow-up at maximum of 20 years
- Cementless THA accounted for 37% of all primary THA (n=1,682,998)
- Top five most implanted cementless THA prostheses were included in this analysis

Acknowledgments

We thank the patients and staff of all the hospitals in England, Wales and Northern Ireland who have contributed data to the National Joint Registry. We are grateful to the Healthcare Quality Improvement Partnership (HQIP), the NJR Steering Committee and staff at the NJR Centre for facilitating this work. The views expressed represent those of the authors and do not necessarily reflect those of the National Joint Registry Steering Committee or the HQIP who do not vouch for how the information is presented.

Results

10 years — 98.1% survivorship with POLARSTEM◊/R3◊[1]

53.4% Lower revision risk with POLARSTEM/R3 compared to class average for cementless hip combinations at 10 years[1]

ODEP[2]
10A* POLARSTEM Cementless Stem
15A* R3 HA Cementless Cup
10A R3 non-HA Cementless Cup




Figure. Cumulative revision of top five most implanted cementless THA prostheses

Conclusions

POLARSTEM with R3 was associated with a 1.9% revision rate at 10 years. This revision rate corresponds to a 53.4% lower revision risk compared with the class average revision rate for cementless constructs in the NJR.

Products may not be available in all markets because product availability is subject to the regulatory and/or medical practices in individual markets. Please contact your Smith+Nephew representative or distributor if you have questions about the availability of Smith+Nephew products in your area. For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.

References:
1. National Joint Registry for England, Wales, and Northern Ireland: 22nd Annual Report Hips. Available at: https://reports.njrcentre.org.uk/Portals/0/PDFdownloads/NJR%2022nd%20Annual%20Report%202025.pdf. Accessed September 18, 2025. **2.** Orthopaedic Data Evaluation Panel (ODEP). Available at: http://www.odep.org.uk. Accessed September 18, 2025.

Smith & Nephew, Inc. 1450 Brooks Road, Memphis, TN 38116, USA.
38144 V5 10/25. Published October 2025.

©2025 Smith+Nephew. All rights reserved. ◊Trademark of Smith+Nephew.
Smith & Nephew Orthopaedics AG, Theilerstrasse 1A, 6300 Zug, Switzerland is the legal manufacturer for POLARSTEM. All Trademarks acknowledged.

Developed by Evidence Communications, Global Clinical & Medical Affairs
www.smith-nephew.com